Robert Dean Prentiss
Nessuna posizione attualmente
Profilo
Robert Dean Prentiss worked as a Director of Finance & Accounting at Idenix Pharmaceuticals LLC from 2011 to 2014.
He also worked as a Controller at Biopure Corp.
Additionally, he worked as a Vice President & Controller at Translate Bio, Inc. from 2017 to 2020.
Prentiss received an undergraduate degree from Salem State University.
Precedenti posizioni note di Robert Dean Prentiss
Società | Posizione | Fine |
---|---|---|
IDENIX PHARMACEUTICALS INC | Direttore Finanziario/CFO | 01/09/2014 |
TRANSLATE BIO, INC. | Direttore Finanziario/CFO | 01/03/2017 |
Biopure Corp.
Biopure Corp. Pharmaceuticals: MajorHealth Technology Biopure Corp. developed, manufactured and marketed oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. The company used patented and proprietary technology to develop and manufacture two products: Hemopure for human use, and Oxyglobin for veterinary use. It has developed Hemopure for the treatment of patients with cardiovascular ischemia. Oxyglobin, its veterinary product treated anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission. Biopure was founded in 1984 and was headquartered in Cambridge, MA. | Comptroller/Controller/Auditor | - |
Formazione di Robert Dean Prentiss
Salem State University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 3 |
---|---|
Biopure Corp.
Biopure Corp. Pharmaceuticals: MajorHealth Technology Biopure Corp. developed, manufactured and marketed oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. The company used patented and proprietary technology to develop and manufacture two products: Hemopure for human use, and Oxyglobin for veterinary use. It has developed Hemopure for the treatment of patients with cardiovascular ischemia. Oxyglobin, its veterinary product treated anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission. Biopure was founded in 1984 and was headquartered in Cambridge, MA. | Health Technology |
Translate Bio, Inc.
Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
Idenix Pharmaceuticals LLC
Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Robert Dean Prentiss